Literature DB >> 7193873

Applications of the human tumor stem cell assay to new drug evaluation and screening.

S E Salmon.   

Abstract

The potential applications of the human tumor stem cell assay to primary drug screening and Phase I-II new drug evaluation are of very broad scope and have not been completely addressed in this exploratory analysis. As in most other areas of science, careful and stepwise testing in many laboratories will be required to confirm or refute the utility of these approaches. Of the two areas discussed, the applications to new drug screening are still most uncertain and subject to change. From my perspective, in vitro growth conditions, for clonogenic human tumor cells, are perhaps at a similar stage of development as culture techniques for bacterial cells were in the 1930s. Availability of those techniques, and a combination of good ideas, serendipidy, and hard work led to the subsequent development of penicillin and other antibiotics which now can be used to cure most forms of infectious disease. The value of a simple and reproducible assay for screening therefore cannot be overemphasized. Applications of the tumor stem cell assay to Phase I-II drug evaluation already show preliminary signs of utility. Given this background and the more limited preclinical data on other agents now under study, broadened testing of this approach to new drug screening appears warranted. If use of an in vitro approach such as this proves successful for both primary and secondary screening, it would not be surprising if significant qualitative and quantitative changes occurred in the areas of new drug development and cancer clinical trials.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7193873

Source DB:  PubMed          Journal:  Prog Clin Biol Res        ISSN: 0361-7742


  11 in total

1.  Advances in oncology.

Authors:  S E Salmon
Journal:  West J Med       Date:  1983-09

2.  High-volume cellular screening for anticancer agents with combinatorial chemical libraries: a new methodology.

Authors:  S E Salmon; R H Liu-Stevens; Y Zhao; M Lebl; V Krchñák; K Wertman; N Sepetov; K S Lam
Journal:  Mol Divers       Date:  1996-10       Impact factor: 2.943

3.  A simple method of delayed processing of tumor tissue in a soft agar clonogenic assay.

Authors:  W Krischke; R Hartmann; M Schneider; H Schönenberger
Journal:  J Cancer Res Clin Oncol       Date:  1988       Impact factor: 4.553

Review 4.  The human tumor cloning assay in cancer drug development. A review.

Authors:  P Agre; T E Williams
Journal:  Invest New Drugs       Date:  1983       Impact factor: 3.850

5.  Usefulness of abrin as a positive control for the human tumor clonogenic assay.

Authors:  S E Salmon; R Liu; C Hayes; J Persaud; R Roberts
Journal:  Invest New Drugs       Date:  1983       Impact factor: 3.850

6.  Review of experience with interferon and drug sensitivity testing of ovarian carcinoma in semisolid agar culture.

Authors:  L B Epstein; S G Marcus
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

7.  Activity of human leukocyte interferon in a human tumor cloning system.

Authors:  D D Von Hoff; J Gutterman; B Portnoy; C A Coltman
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

8.  In vitro and in vivo chemotherapy screening of the divalent cation chelator 1,10-orthophenanthroline.

Authors:  P S Cohen; S D Smith
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

9.  Interactions of human leukocyte interferon with vinca alkaloids and other chemotherapeutic agents against human tumors in clonogenic assay.

Authors:  M S Aapro; D S Alberts; S E Salmon
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

10.  In vitro antitumor effect of recombinant human tumor necrotizing factor on cultured human cancer cell lines and freshly isolated lung cancer cells by the human tumor clonogenic assay.

Authors:  Y Sasaki; F Kanzawa; H Takahashi; Y Matsushima; H Nakano; K Nakagawa; W S Hong; K Minato; Y Fujiwara; N Saijo
Journal:  Invest New Drugs       Date:  1987-12       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.